Insulet Financials

PODD Stock  USD 266.68  16.80  5.93%   
Based on the key indicators related to Insulet's liquidity, profitability, solvency, and operating efficiency, Insulet is performing exceptionally good at this time. It has a great probability to report excellent financial results in March. At present, Insulet's Total Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Cash is expected to grow to about 1 B, whereas Other Assets are forecasted to decline to 1.09. Key indicators impacting Insulet's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio3.43.5793
Notably Down
Slightly volatile
The essential information of the day-to-day investment outlook for Insulet includes many different criteria found on its balance sheet. An individual investor should monitor Insulet's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Insulet.

Net Income

439.21 Million

  

Insulet Earnings Geography

Please note, the presentation of Insulet's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Insulet's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Insulet's management manipulating its earnings.

Insulet Stock Summary

Insulet competes with DexCom, Integra LifeSciences, Senseonics Holdings, Edwards Lifesciences, and Tandem Diabetes. Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts. Insulet Corp operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 2300 people.
Specialization
Health Care, Health Care Equipment & Services
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS45784P1012
CUSIP45784P101
LocationMassachusetts; U.S.A
Business Address100 Nagog Park,
SectorHealth Care Equipment & Supplies
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.insulet.com
Phone978 600 7000
CurrencyUSD - US Dollar

Insulet Key Financial Ratios

Insulet Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets1.9B2.0B2.3B2.6B3.1B3.2B
Net Debt96.1M457.2M727.1M711.6M(869.6M)(826.1M)
Cash947.6M791.6M674.7M704.2M953.4M1.0B
Other Assets79M106.1M147.1M1.01.151.09
Total Liab1.3B1.5B1.8B1.9B1.9B2.0B
Total Current Assets1.2B1.3B1.3B1.6B1.9B2.0B
Other Current Liab132.7M162.5M306.4M382.6M424.8M446.0M
Short Term Debt15.6M25.1M27.5M49.4M83.8M52.1M
Retained Earnings(666.3M)(649.5M)(584.3M)(378M)40.3M42.3M
Accounts Payable54.1M37.7M30.8M19.2M19.8M19.8M
Other Current Assets63M74M86.9M116.4M255M267.8M
Other Liab7M17.8M14.9M8.3M9.5M5.4M
Long Term Debt1.0B1.2B1.4B1.4B1.3B1.4B
Net Receivables83.8M161M205.6M359.7M252.5M265.1M
Inventory154.3M303.2M346.8M402.6M430.4M451.9M
Net Tangible Assets22.9M535.1M479.9M349.2M401.6M421.7M
Long Term Debt Total887.9M1.0B1.2B1.4B1.6B1.7B
Capital Surpluse749M1.3B1.2B1.0B1.2B899.1M

Insulet Key Income Statement Accounts

202020212022202320242025 (projected)
Interest Expense45.1M61.2M26.7M36.2M(3.2M)(3.0M)
Operating Income(600K)66.7M(26.7M)220M308.9M324.3M
Ebit54.9M82.2M46.3M250.8M288.4M302.8M
Research Development146.8M160.1M180.2M205M219.6M230.6M
Ebitda110.3M139.6M109.5M323.6M308.9M324.3M
Net Income6.8M16.8M4.6M206.3M418.3M439.2M
Total Revenue904.4M1.1B1.3B1.7B2.1B2.2B
Gross Profit582.3M752.1M805.6M1.2B1.4B1.5B
Cost Of Revenue322.1M346.7M499.7M537.2M625.9M657.2M
Income Before Tax9.7M20.5M9.8M214.6M300.2M315.2M
Interest Income3M500K9.8M28.9M39.5M41.5M
Net Interest Income(45.1M)(61.2M)(26.7M)(9.8M)(3.2M)(3.4M)

Insulet Key Cash Accounts

202020212022202320242025 (projected)
Change In Cash708.3M(115.6M)(116.7M)14.5M249.2M261.7M
Free Cash Flow(82.5M)(190.8M)(38.3M)36.5M305.4M320.7M
Depreciation55.4M57.4M63.2M72.8M80.8M84.8M
Other Non Cash Items46M41.4M12.8M8.9M(1.2M)(1.1M)
Capital Expenditures166.5M122.7M157.3M75.6M124.9M131.1M
Net Income6.8M16.8M4.6M206.3M418.3M439.2M
End Period Cash Flow922M806.4M689.7M704.2M953.4M1.0B
Change To Inventory(50.5M)(154.4M)(49.1M)(53.6M)(32.4M)(34.0M)
Net Borrowings31.2M128.3M(464.9M)(39.8M)(35.8M)(34.0M)
Change To Netincome43M40M81.1M47.9M55.1M40.7M
Investments180.5M40M(7.8M)(176.2M)(146.2M)(138.9M)

Insulet Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Insulet's current stock value. Our valuation model uses many indicators to compare Insulet value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Insulet competition to find correlations between indicators driving Insulet's intrinsic value. More Info.
Insulet is considered to be number one stock in return on equity category among its peers. It is rated below average in return on asset category among its peers reporting about  0.16  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Insulet is roughly  6.33 . At present, Insulet's Return On Equity is projected to increase slightly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Insulet by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Insulet Systematic Risk

Insulet's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Insulet volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Insulet correlated with the market. If Beta is less than 0 Insulet generally moves in the opposite direction as compared to the market. If Insulet Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Insulet is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Insulet is generally in the same direction as the market. If Beta > 1 Insulet moves generally in the same direction as, but more than the movement of the benchmark.

Insulet Thematic Clasifications

Insulet is part of several thematic ideas from Obamacare Repeal to Baby Boomer Prospects. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic Ideas
Today, most investors in Insulet Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Insulet's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Insulet growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.45

At present, Insulet's Price Earnings To Growth Ratio is projected to decrease significantly based on the last few years of reporting.

Insulet February 25, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Insulet help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Insulet. We use our internally-developed statistical techniques to arrive at the intrinsic value of Insulet based on widely used predictive technical indicators. In general, we focus on analyzing Insulet Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Insulet's daily price indicators and compare them against related drivers.

Complementary Tools for Insulet Stock analysis

When running Insulet's price analysis, check to measure Insulet's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Insulet is operating at the current time. Most of Insulet's value examination focuses on studying past and present price action to predict the probability of Insulet's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Insulet's price. Additionally, you may evaluate how the addition of Insulet to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Bonds Directory
Find actively traded corporate debentures issued by US companies